Ovarian Cancer Clinical Trials

153 studies are recruiting for ovarian cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Precision NextGen Oncology & Research Center, Beverly Hills, California

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   76 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Distance-Based Exercise to Preserve Function and Prevent Disability

   This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side e…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Kaiser Permanente Dublin, Dublin, California

   Locations

   23 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT07059884 on ClinicalTrials.gov

4. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

   This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with relapsed/refractory, locally advanced inoperable, or metastatic solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dothan Hematology & Oncology, Dothan, Alabama

   Locations

   5 in total

   Run by

   Radiopharm Theranostics, Ltd

   See if you can join NCT07189871 on ClinicalTrials.gov

5. A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

   A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 06, Maumee, Ohio

   Locations

   3 in total

   Run by

   TwoStep Therapeutics, Inc.

   See if you can join NCT07814248 on ClinicalTrials.gov

6. Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

   The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This prop…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mayo Clinic, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Mayo Clinic

   See if you can join NCT05051722 on ClinicalTrials.gov

7. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

   Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Gilbert, Arizona

   Locations

   20 in total

   Run by

   AstraZeneca

   See if you can join NCT05877599 on ClinicalTrials.gov

8. DESTINY-PANTUMOUR04

   This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

   Stage

   Not phased

   Ages

   18 to 130

   Site

   Research Site, Birmingham, Alabama

   Locations

   18 in total

   Run by

   AstraZeneca

   See if you can join NCT07124000 on ClinicalTrials.gov

9. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

   This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Comprehensive Cancer Center, Duarte, California

   Locations

   28 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT04590326 on ClinicalTrials.gov

10. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage

    Phase 2

    Ages

    18 to 130

    Site

    Research Site, Los Angeles, California

    Locations

    96 in total

    Run by

    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

11. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

12. Prehabilitation in High-risk Oncologic Surgery

    The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery. Prehabilitation is supportive care given before surgery to help patients prepare physically, nutritional…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania

    Run by

    Fox Chase Cancer Center

    See if you can join NCT07638410 on ClinicalTrials.gov

13. Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer

    Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of New Mexico Cancer Center, Albuquerque, New Mexico

    Run by

    New Mexico Cancer Research Alliance

    See if you can join NCT03943316 on ClinicalTrials.gov

14. Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

    This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effect…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04038619 on ClinicalTrials.gov

15. BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

    The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    25 in total

    Run by

    BioInvent International AB

    See if you can join NCT04752826 on ClinicalTrials.gov

16. Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

    The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning chemotherapy, in part…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05316129 on ClinicalTrials.gov

17. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Usa Health Mitchell Cancer Institute, Mobile, Alabama

    Locations

    74 in total

    Run by

    Incyte Corporation

    See if you can join NCT07023627 on ClinicalTrials.gov

18. A Study of Isoquercetin in People With Ovarian Cancer

    The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07303894 on ClinicalTrials.gov

19. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

    This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    56 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06787612 on ClinicalTrials.gov

20. DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

    The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting ch…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts

    Locations

    3 in total

    Run by

    Elizabeth Stover, MD, PhD

    See if you can join NCT06964009 on ClinicalTrials.gov

21. Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

    This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06646627 on ClinicalTrials.gov

22. Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

    The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence. The main question[s] it aims to answer [is/are]: Does psilocybin assisted therapy improve fear of cancer recurrenc…

    Stage

    Phase 1

    Ages

    21 and older

    Site

    Outpatient CTRC, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT06430541 on ClinicalTrials.gov

23. Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

    This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida

    Locations

    6 in total

    Run by

    ArriVent BioPharma, Inc.

    See if you can join NCT07755436 on ClinicalTrials.gov

24. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    5 in total

    Run by

    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

25. Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

    The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Start Cal, Los Angeles, California

    Locations

    8 in total

    Run by

    Tubulis GmbH

    See if you can join NCT07736937 on ClinicalTrials.gov